Advertisement

Taurine 8 pp 189-198 | Cite as

Taurine Enhances Anticancer Activity of Cisplatin in Human Cervical Cancer Cells

  • Taehee Kim
  • An Keun KimEmail author
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 776)

Abstract

Taurine is a nonessential amino acid and has a variety of physiological and pharmacological effects. Recently, protective effects of taurine against anticancer drugs on normal cells were investigated. But anticancer effects of taurine on cancer cells remain poorly understood. Therefore, we investigated the anticancer effects of taurine alone and combination of cisplatin with taurine in human cervical cancer cells. Single treatment of taurine decreased cell proliferation in a time- and dose-dependent manner. In co-treatment of cisplatin with taurine, cell proliferation was more decreased than single treatment of cisplatin. Reduced cell proliferation was caused by apoptosis induction. Thus, after treatment of cisplatin with taurine, apoptotic cells were investigated. Apoptotic cells were increased more than taurine or cisplatin alone. Induction of apoptosis was related to p53 expression and activation of caspase-3, caspase-6, caspase-7, and caspase-9. In present study, the results indicated that co-treatment of cisplatin with taurine was more effective than single treatment of cisplatin.

Keywords

Single Treatment Anticancer Effect Reduce Cell Proliferation Decrease Cell Proliferation Human Cervical Cancer Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This research was supported by the Sookmyung Women’s University Research Grants 2010.

References

  1. Barbeau A (1975) The brain, the heart and taurine. Can J Neurol Sci 2:343–346PubMedGoogle Scholar
  2. Boulikas T, Vougiouka M (2004) Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs. Oncol Rep 11:559–595PubMedGoogle Scholar
  3. Bremer E, van Dam G, Kroesen BJ, de Leij L, Helfrich W (2006) Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med 12:382–393PubMedCrossRefGoogle Scholar
  4. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X (1999) Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15:269–290PubMedCrossRefGoogle Scholar
  5. Chen XC, Pan ZL, Liu DS, Han X (1998) Effect of taurine on human fetal neuron cells: proliferation and differentiation. Adv Exp Med Biol 442:397–403PubMedGoogle Scholar
  6. Chen YX, Zhang XR, Xie WF, Li S (2004) Effects of taurine on proliferation and apoptosis of hepatic stellate cells in vitro. Hepatobiliary Pancreat Dis Int 3:106–109PubMedGoogle Scholar
  7. Chène P (2001) Targeting p53 in cancer. Curr Med Chem Anticancer Agents 1:151–161PubMedCrossRefGoogle Scholar
  8. Danielsson H, Sjövall J (1975) Bile acid metabolism. Annu Rev Biochem 44:233–253PubMedCrossRefGoogle Scholar
  9. Fan TJ, Han KH, Cong RS, Kiang J (2005) Caspase-family proteases and apoptosis. Acta Biochim Biophys Sin 37:719–727PubMedCrossRefGoogle Scholar
  10. Ghavami G, Kazemali MR, Sardari S (2011) Informatics of drug synergism in naturally occurring anticancer agents. Recent Pat Anticancer Drug Discov 6:26–44PubMedCrossRefGoogle Scholar
  11. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409–422PubMedGoogle Scholar
  12. Gottlieb JA, Drewinko B (1975) Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep 59:621–628PubMedGoogle Scholar
  13. Hamaguchi T, Azuma J, Awata N, Ohta H, Takihara K, Harada H, Kishimoto S, Sperelakis N (1988) Reduction of doxorubicin-induced cardiotoxicity in mice by taurine. Res Commun Chem Pathol Pharmacol 59:21–30PubMedGoogle Scholar
  14. Hamaguchi T, Azuma J, Harada H, Takahashi K, Kishimoto S, Schaffer SW (1989) Protective effect of taurine against doxorubicin-induced cardiotoxicity in perfused chick hearts. Pharmacol Res 21:729–734PubMedCrossRefGoogle Scholar
  15. Hernández-Benítez R, Ramos-Mandujano G, Pasantes-Morales H (2012) Taurine stimulates proliferation and promotes neurogenesis of mouse adult cultured neural stem/progenitor cells. Stem Cell Res 9(1):24–34PubMedCrossRefGoogle Scholar
  16. Hong SJ, Dawson TM, Dawson VL (2004) Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci 25:259–264PubMedCrossRefGoogle Scholar
  17. Huxtable RJ (1992) Physiological actions of taurine. Physiol Rev 72:101–163PubMedGoogle Scholar
  18. Ito T, Muraoka S, Takahashi K, Fujio Y, Schaffer SW, Azuma J (2009) Beneficial effect of taurine treatment against doxorubicin-induced cardiotoxicity in mice. Adv Exp Med Biol 643:65–74PubMedCrossRefGoogle Scholar
  19. Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M (1999) Apoptosis. Molecules and mechanisms. Adv Exp Med Biol 457:217–236PubMedCrossRefGoogle Scholar
  20. Lima L, Cubillos S (1998) Taurine-stimulated outgrowth from the retina is impaired by protein kinase C activators and phosphatase inhibitors. Adv Exp Med Biol 442:423–430PubMedGoogle Scholar
  21. Maclaine NJ, Hupp TR (2009) The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging 1:490–502PubMedGoogle Scholar
  22. McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf 13:228–244PubMedCrossRefGoogle Scholar
  23. Nimmanapalli R, Bhalla K (2003) Targets in apoptosis signaling: promise of selective anticancer therapy. Methods Mol Biol 223:465–483PubMedGoogle Scholar
  24. Porter AG, Jänicke RU (1999) Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6:99–104PubMedCrossRefGoogle Scholar
  25. Saad SY, Al-Rikabi AC (2002) Protection effects of Taurine supplementation against cisplatin-induced nephrotoxicity in rats. Chemotherapy 48:42–48PubMedCrossRefGoogle Scholar
  26. Saif MW, Tytler E, Lansigan F, Brown DM, Husband AJ (2009) Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. Expert Opin Investig Drugs 18:469–479PubMedCrossRefGoogle Scholar
  27. Sato S, Yamate J, Saito T, Hosokawa T, Saito S, Kurasaki M (2002) Protective effect of taurine against renal interstitial fibrosis of rats induced by cisplatin. Naunyn Schmiedebergs Arch Pharmacol 365:277–283PubMedCrossRefGoogle Scholar
  28. Suganuma M, Saha A, Fujiki H (2011) New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci 102:317–323PubMedCrossRefGoogle Scholar
  29. Yu J, Zhang L (2004) Apoptosis in human cancer cells. Curr Opin Oncol 16:19–24PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.College of Pharmacy, Sookmyung Women’s UniversitySeoulSouth Korea

Personalised recommendations